Evidence map›Paper›PMID 40062317›Full record

ArticleWellcome open research2025

Insights of SEDRIC, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium.

Nicholas Feasey, Raheelah Ahmad, Elizabeth Ashley, Rifat Atun, Kate S Baker, Francesca Chiari, H Rogier van Doorn, Alison Holmes, Timothy Jinks, Andrew Jermy and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Wellcome open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Nicholas FeaseyDepartment of Clinical Sciences,, Liverpool School of Tropical Medicine, Liverpool, UK.ORCID https://orcid.org/0000-0003-4041-1405
Raheelah AhmadNIHR Health Protection Research Unit (HPRU) in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.ORCID https://orcid.org/0000-0002-4294-7142
Elizabeth AshleyUniversity of Oxford Nuffield Department of Medicine, Oxford, England, UK.ORCID https://orcid.org/0000-0002-7620-4822
Rifat AtunHarvard School of Public Health, Boston, Massachusetts, USA.
Kate S BakerGenetics, University of Cambridge, Cambridge, UK.
Francesca ChiariDrug resistant infections Priority Programme, Wellcome Trust, London, UK.
H Rogier van DoornUniversity of Oxford Nuffield Department of Medicine, Oxford, England, UK.ORCID https://orcid.org/0000-0002-9807-1821
Alison HolmesNIHR Health Protection Research Unit (HPRU) in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-5554-5743
Timothy JinksDrug resistant infections Priority Programme, Wellcome Trust, London, UK.
Andrew JermyGerminate, Germinate Science Consulting Ltd, Suffolk, UK.
Jyoti JoshiInternational Centre for AMR Solutions, Copenhagen, Denmark.
Souha S KanjDivision of Infectious Diseases, Internal Medicine Department, and Center for Infectious Diseases Research, American University of Beirut Medical Center, Beirut, Lebanon.ORCID https://orcid.org/0000-0001-6413-3396
Matt KingARCTA solutions Ltd, Hampshire, UK.
Direk LimmathurotsakulMahidol Oxford Tropical Medicine Research Unit, Bangkok, Bangkok, Thailand.ORCID https://orcid.org/0000-0001-7240-5320
Janet MidegaDrug resistant infections Priority Programme, Wellcome Trust, London, UK.
Mirfin MpunduReAct Africa, Lusaka, Zambia.
Jamie NunnLondon School of Hygiene & Tropical Medicine, University of London, London, England, UK.
Iruka N OkekeDepartment of Pharmaceutical Microbiology, University of Ibadan, Ibadan, Oyo, Nigeria.ORCID https://orcid.org/0000-0002-1694-7587
Stuart ReidThe Royal Veterinary College, London, England, UK.
Dawn SievertAntimicrobial Resistance Coordination and Strategy Unit, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atanta, Georgia, USA.
Paul TurnerUniversity of Oxford Nuffield Department of Medicine, Oxford, England, UK.ORCID https://orcid.org/0000-0002-1013-7815
Kamini WaliaIndian Council of Medical Research, New Delhi, Delhi, India.
Sharon J PeacockMedicine, University of Cambridge, Cambridge, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

The increasing threat from infection with drug-resistant pathogens is among the most serious public health challenges of our time. Formed by Wellcome in 2018, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium (SEDRIC) is an international think tank whose aim is to inform policy and change the way countries track, share, and analyse data relating to drug-resistant infections, by defining knowledge gaps and identifying barriers to the delivery of global surveillance. SEDRIC delivers its aims through discussions and analyses by world-leading scientists that result in recommendations and advocacy to Wellcome and others. As a result, SEDRIC has made key contributions in furthering global and national actions. Here, we look back at the work of the consortium between 2018-2024, highlighting notable successes. We provide specific examples where technical analyses and recommendations have helped to inform policy and funding priorities that will have real-world impact on the surveillance and epidemiology of infections with drug-resistant pathogens.

Indexed as

Antimicrobial resistancesurveillance

Identifiers

PMID40062317
PMCPMC11885901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.